MedPath

CAR-T Therapy Shows Promise in Lenalidomide-Refractory Multiple Myeloma

7 months ago1 min read

Key Insights

  • CARTITUDE-4 trial results show promise for patients with lenalidomide-refractory multiple myeloma after 1-3 prior lines of therapy, indicating a potential new treatment option.

  • Five-year follow-up data from the TRANSCEND-NHL-001 trial were discussed, providing insights into the long-term efficacy and safety of CAR-T cell therapy in lymphoma.

  • Bendamustine was found to be an effective alternative to fludarabine for lymphodepletion in large B-cell lymphoma patients receiving CD19-directed CAR-T therapy, addressing fludarabine shortages.

CAR-T therapy is showing promise in treating patients with lenalidomide-refractory multiple myeloma (MM). The results come from patients with lenalidomide-refractory MM treated in the CARTITUDE-4 trial after 1 to 3 lines of prior therapy.

TRANSCEND-NHL-001 Trial Update

The clinical director of lymphoma services at the University of Colorado discussed 5-year follow-up data from the TRANSCEND-NHL-001 clinical trial, offering insights into the long-term outcomes of CAR-T cell therapy in lymphoma patients.

Bendamustine as Fludarabine Alternative

In response to fludarabine shortages, research indicates that lymphodepletion with bendamustine is an effective alternative for patients with large B-cell lymphoma undergoing CD19-directed CAR T-cell therapy. This finding provides a crucial option for clinicians facing drug supply challenges.

Exa-cel Data Update

The Medical Director of Pediatric Hematology/Oncology at Sarah Cannon Research Institute presented the latest data update from the CLIMB SCD-121 trial evaluating exa-cel, offering new insights into its efficacy and safety profile.

Tabelecleucel for EBV-Associated Lymphoproliferative Disease

With an FDA decision anticipated in January, tabelecleucel has demonstrated sustained safety and efficacy with extended follow-up in treating Epstein-Barr virus-associated post-transplant lymphoproliferative disease, reinforcing its potential as a therapeutic option.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.